Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study

Arthritis Research and Therapy

Volumn 20, Issue 1, 2018, Pages

  Tanaka, Yoshiya ^a   Kameda, Hideto ^b   Saito, Kazuyoshi ^a,c   Kaneko, Yuko ^d   Tanaka, Eiichi ^e   Yasuda, Shinsuke ^f   Tamura, Naoto ^g   Fujio, Keishi ^h   Fujii, Takao ⁱ   Kojima, Toshihisa ^j   Anzai, Tatsuhiko ^k   Hamada, Chikuma ^l   Fujino, Yoshihisa ^a   Matsuda, Shinya ^a   Kohsaka, Hitoshi ^m  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c Tobata Hospital   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f HOKKAIDO UNIVERSITY   (Japan)

^g JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^j NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k EPS Corporation   (Japan)

^l TOKYO UNIVERSITY OF SCIENCE   (Japan)

^m TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

more..

Author keywords

Disease activity; Quality of life; Rheumatoid arthritis; Tocilizumab; Work disability

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ABSENTEEISM; ADULT; AGED; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL PRACTICE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DAS28; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FRENCHAY ACTIVITIES INDEX; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HOUSEKEEPING; HUMAN; INVERSE PROBABILITY OF TREATMENT WEIGHTING; JAPANESE (PEOPLE); LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OCCUPATION; OCCUPATIONAL HEALTH; PRESENTEEISM; PROBABILITY; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; STOMATITIS; TREATMENT DURATION; WORK DISABILITY; WORKER; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; DRUG EFFECT; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASIAN CONTINENTAL ANCESTRY GROUP; EFFICIENCY; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 85050262984     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-018-1647-3     Document Type: Article

References (32)

1. Hone D, Cheng A, Watson C, Huang B, Bitman B, Huang XY, et al. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States. Arthritis Care Res (Hoboken). 2013;65:1564-72.
2. Furuya H, Kasama T, Isozaki T, Umemura M, Otsuka K, Isojima S, et al. Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis. J Multidiscip Healthc. 2013;6:25-30.
3. Zhang W, Sun H, Emery P, Sato R, Singh A, Freundlich B, et al. Does achieving clinical response prevent work stoppage or work absence among employed patients with early rheumatoid arthritis? Rheumatology (Oxford). 2012;51:270-4.
4. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3-15.
5. Takeuchi T, Nakajima R, Komatsu S, Yamazaki K, Nakamura T, Agata N, et al. Impact of adalimumab on work productivity and activity impairment in Japanese patients with rheumatoid arthritis: large-scale, prospective, single-cohort ANOUVEAU study. Adv Ther. 2017;34:686-702.
6. Verstappen SM. Rheumatoid arthritis and work: the impact of rheumatoid arthritis on absenteeism and presenteeism. Best Pract Res Clin Rheumatol. 2015;29:495-511.
7. Bertin P, Fagnani F, Duburcq A, Woronoff AS, Chauvin P, Cukierman G, et al. Impact of rheumatoid arthritis on career progression, productivity, and employability: the PRET study. J Bone Spine. 2016;83:47-52.
8. van Vilsteren M, Boot CR, Knol DL, van Schaardenburg D, Voskuyl AE, Steenbeek R, et al. Productivity at work and quality of life in patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2015;16:107.
9. Almoallim H, Kamil A. Rheumatoid arthritis: should we shift the focus from "treat to target" to "treat to work?". Clin Rheumatol. 2013;32:285-7.
10. Rheumatoid Arthritis (RA) 2017. https://www.cdc.gov/arthritis/basics/rheumatoid-arthritis.html Accessed 2 July 2018.
11. Tanaka E, Inoue E, Hoshi D, Shidara K, Sugimoto N, Inoue Y, et al. Assessment of work productivity and activity impairment in patients with rheumatoid arthritis based on the Institute of Rheumatology Rheumatoid Arthritis (IORRA) cohort database (FRI0124). Ann Rheum Dis. 2013;72:A412.
12. Beaton DE, Dyer S, Boonen A, Verstappen SM, Escorpizo R, Lacaille DV, et al. OMERACT filter evidence supporting the measurement of at-work productivity loss as an outcome measure in rheumatology research. J Rheumatol. 2016;43:214-22.
13. Tang K, Beaton DE, Boonen A, Gignac MA, Bombardier C. Measures of work disability and productivity: rheumatoid arthritis specific work productivity survey (WPS-RA), workplace activity limitations scale (WALS), work instability scale for rheumatoid arthritis (RA-WIS), work limitations questionnaire (WLQ), and work productivity and activity impairment questionnaire (WPAI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):337-49.
14. Alghasham A, Rasheed Z. Therapeutic targets for rheumatoid arthritis: progress and promises. Autoimmunity. 2014;47:77-94.
15. Tanaka T, Narazaki M, Ogata A, Kishimoto T. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin Immunol. 2014;26:88-96.
16. Tocilizumab package insert for Japan, https://chugai-pharm.jp/hc/ss/pr/drug/act_via0200/pi/PDF/act_pi.pdf. Accessed 2 July 2018.
17. Fujino Y, Uehara M, Izumi H, Nagata T, Muramatsu K, Kubo T, et al. Development and validity of a work functioning impairment scale based on the Rasch model among Japanese workers. J Occup Health. 2015;57:521-31.
18. Shiratsuchi M, Saeki S, Hachisuka K. Japanese version of the self-rating Frenchay activities index and its clinical application and standard values. General Rehabilitation. 1999;27:469-74.
19. Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, et al. Estimating an EQ-5D population value set. The case of Japan. Health Econ. 2002;11:341-53.
20. Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A, et al. Validation of a Japanese version of the Stanford health assessment questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003;49:784-8.
21. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-45.
22. Furukawa TA, Kessler R, Slade T, Andrews G. The performance of the K6 and K10 screening scales for psychological distress in the Australian National Survey of mental health and well-being. Psychol Med. 2003;33:357-62.
23. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7.
24. Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum. 2009;61:1592-600.
25. Machado DA, Guzman RM, Xavier RM, Simon JA, Mele L, Pedersen R, et al. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region. J Clin Rheumatol. 2014;20:25-33.
26. Bae SC, Gun SC, Mok CC, Khandker R, Nab HW, Koenig AS, et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskelet Disord. 2013;8(14):13.
27. Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, et al. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Dis. 2017;76:1853-61.
28. Tanaka Y, Yamazaki K, Nakajima R, Komatsu S, Igarashi A, Tango T, et al. Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study. Mod Rheumatol. 2018;28(1):39-47.
29. Choy EHS, Calabrese LH. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/kex391.
30. Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther. 2014;16:R56.
31. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2014;41:15-23.
32. Yamamoto K, Goto H, Hirao K, Nakajima A, Origasa H, Tanaka K, et al. Longterm safety of tocilizumab: results from 3 years of follow-up postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. J Rheumatol. 2015;42:1368-75.